H-Index
12
Scimago Lab
powered by Scopus
eISSN: 1941-5923

Logo



Get your full text copy in PDF

Chronic neutrophilic leukemia with dysplastic features following therapy for Hodgkin lymphoma – evolution into acute myeloid leukemia

Giovanni Carulli, Antonio Azzarà, Ortenzio Fabiani, Elisa Cannizzo, Virginia Ottaviano, Eugenio M. Ciancia, Gabriele Buda, Alessandra Marini, Mario Petrini

Am J Case Rep 2010; 11:159-162

ID: 881140


Background: Chronic neutrophilic leukemia (CNL) is a rare disease and can be characterized by dysplastic changes (CNL-D) only in very few cases. It has never been described after treatment for Hodgkin lymphoma (HL).
Case Report: A 41-year-old woman, previously treated with chemo-radiotherapy for HL, presented with absolute neutrophilia, anemia and thrombocytopenia. All circulating neutrophils displayed Pelger-like features, with round-shaped nuclei. In addition, an evident clumping of chromatin into blocks separated by clear zones was observed in a significant percentage of Pelger-like neutrophils. Electron microscopy confirmed these findings. Bone marrow showed trilineage dysplasia. CNL-D was diagnosed. Nine months later, transformation into acute myeloid leukemia (M1 of FAB classification) was observed, with immunophenotype characterized by the expression of CD34, CD33, CD13, CD117 and HLA-DR. The patient died with a clinical picture of therapy-resistant disease.
Conclusions: Therapy-related myelodysplasia and acute leukemia can be observed after treatment for HL. We describe the first case of CNL-D following therapy for HL. CNL is frequently characterized by a fatal clinical course, and the presence of myelodysplastic features worsen prognosis. Thus, it is important to recognise this clinical entity in order to develop appropriate therapeutic strategies.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree